|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 886.6 DKK | +2.28% |
|
+2.36% | +27.00% |
| Apr. 25 | NOVO NORDISK : JP Morgan gives a Buy rating | ZD |
| Apr. 25 | Scholz promises support for pharma sector in Germany as Merck invests | RE |
OSLO, March 5 (Reuters) - Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, according to a large late-stage study.
"The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events (MACE) and death of 24%," it said in a statement. (Reporting by Stine Jacobsen and Maggie Fick Editing by Josephine Mason and Terje Solsvik)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 886.6 DKK | +2.28% | +2.36% | 566B | ||
| 133.5 USD | +0.56% | +4.45% | 11.71B | ||
| 37.42 EUR | -0.98% | +2.18% | 11.72B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +27.00% | 566B | |
| +25.83% | 661B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B | |
| -11.77% | 144B |
NOVO NORDISK A/S 
